Clinical trial · Observational
Studies on Tumors of the Thyroid
Studies on Thyroid Nodules and Thyroid Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Participants in this study will be patients diagnosed with or suspected to have a thyroid nodule or thyroid cancer. The main purpose of this study is to further understand the methods for the diagnosis and treatment of thyroid nodules and thyroid cancer. Many of the test performed are in the context of standard medical care that is offered to all patients with thyroid nodules or thyroid cancer. Other tests are performed for research purposes. In addition, blood and tissue samples will be taken for research and genetic studies.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Follicular Thyroid Cancer | Thyroid Gland Follicular Carcinoma | ALIAS | 0.90 |
| Hurthle Cell Thyroid Cancer | Thyroid Gland Oncocytic Carcinoma | ALIAS | 0.90 |
| Papillary Thyroid Cancer | Thyroid Gland Papillary Carcinoma | ALIAS | 0.90 |
| Tall Cell Variant Thyroid Cancer | Thyroid Gland Neoplasm | PROBABILISTIC | 0.70 |
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 68-Gallium Dotatate | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- thyroid cancer
- description
- Patients with thyroid cancer
- interventionNames
- Drug: 68-Gallium Dotatate
- label
- thyroid nodules
- description
- Patients with thyroid nodules
- interventionNames
- Drug: 68-Gallium Dotatate
Primary outcomes (2)
- measure
- Evaluation of thyroid cancer
- timeFrame
- As clinically indicated
- description
- Blood draws, CT and other scans, physical exams, surgery (if applicable), thyroid biopsy (if applicable).
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 6 Months
- Maximum age
- 98 Years
Show eligibility criteria text
* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Male or female, adults or children \>= 6 months+. 2. Patients with known or suspected thyroid nodules and/or thyroid cancer. 3. At risk family members of patients who have a genetic susceptibility to developing thyroid cancer. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: 1\. Serious underlying medical conditions that restrict diagnostic testing or therapy such as renal failure, congestive cardiac failure or active coexisting non-thyroid carcinoma requiring intervention before thyroid cancer is addressed.
References
Publications (2)
- BACKGROUNDKlubo-Gwiezdzinska J, Wartofsky L. The Role of Molecular Diagnostics in the Management of Indeterminate Thyroid Nodules. J Clin Endocrinol Metab. 2018 Sep 1;103(9):3507-3510. doi: 10.1210/jc.2018-01081. PMID 30032182
- BACKGROUNDThakur S, Tobey A, Daley B, Auh S, Walter M, Patel D, Nilubol N, Kebebew E, Patel A, Jensen K, Vasko V, Klubo-Gwiezdzinska J. Limited Utility of Circulating Cell-Free DNA Integrity as a Diagnostic Tool for Differentiating Between Malignant and Benign Thyroid Nodules With Indeterminate Cytology (Bethesda Category III). Front Oncol. 2019 Sep 18;9:905. doi: 10.3389/fonc.2019.00905. eCollection 2019. PMID 31620364